OLVI-VEC-022 A Randomized Phase 3 Study Assessing the Efficacy and Safety
of Olvi-Vec followed by Platinum-doublet Chemotherapy and
Bevacizumab Compared with Platinum-doublet Chemotherapy and
Bevacizumab in Women with Platinum-Resistant/Refractory
Ova

NCT05281471

A Randomized Phase 3 Study Assessing the Efficacy and Safety
of Olvi-Vec followed by Platinum-doublet Chemotherapy and
Bevacizumab Compared with Platinum-doublet Chemotherapy and
Bevacizumab in Women with Platinum-Resistant/Refractory
Ovarian Cancer (OnPrime Study

Associated Conditions

Ovarian, Fallopian, or Primary Peritoneum Cancer

Principal Investigator

Robert Holloway

Sponsor

Genelux

You are invited to take part in a research study. This research study is studying Olvi-Vec as a possible treatment for platinum-resistant or platinum-refractory ovarian cancer including fallopian tube cancer and peritoneal carcinomatosis (collectively termed PRROC). Genelux Corporation is sponsoring this research study.

This study is currently enrolling.